[1]JournalofMedicinalChemistry,2014,vol.57,#10,p.4173-4184
[2]Patent:WO2015/167825,2015,A1,.Locationinpatent:Page/Pagecolumn102
[1]JournalofMedicinalChemistry,2014,vol.57,#10,p.4173-4184
[2]JournalofMedicinalChemistry,2014,vol.57,#10,p.4173-4184
[3]Patent:WO2015/167825,2015,A1,
[1]JournalofMedicinalChemistry,2014,vol.57,#10,p.4173-4184
[2]JournalofMedicinalChemistry,2014,vol.57,#10,p.4173-4184
[3]Patent:WO2015/167825,2015,A1,
[1]JournalofMedicinalChemistry,2014,vol.57,p.4173-4184
[2]JournalofMedicinalChemistry,2014,vol.57,p.4173-4184
[3]Patent:WO2015/167825,2015,A1
Title: Development of second generation EP2 antagonists with high selectivity.
Journal: European journal of medicinal chemistry 20140723
Title: Isolation of streptococcal nuclease B by batch adsorption.
Journal: Journal of clinical microbiology 19751201
Title: Jiang J, et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-3596.
Title: Kang X, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 2017 Aug 25;7(1):9459.